American Heart Journal
Volume 147, Issue 2 , Pages 202-209 , February 2004

Antibiotics for secondary prevention of coronary artery disease: an ACES hypothesis but we need to PROVE IT

  • Eli V Gelfand, MD

      Affiliations

    • Cardiovascular Division, Beth Israel Deaconess Medical Center, Boston, Mass, USA
    • Thrombolysis in Myocardial Infarction (TIMI) Study Group, Cardiovascular Division, Brigham and Women's Hospital, Boston, Mass, USA
    • ,
  • Christopher P Cannon, MD

      Affiliations

    • Thrombolysis in Myocardial Infarction (TIMI) Study Group, Cardiovascular Division, Brigham and Women's Hospital, Boston, Mass, USA
    • Corresponding Author InformationReprint requests: Christopher P. Cannon, MD, TIMI Study Group, Cardiovascular Division, Brigham and Women's Hospital, 75 Francis Street, Boston, MA 02115, USA.

Received 13 June 2003 ,Accepted 5 September 2003.

References 

  1. Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation. 2002;105:1135–1143
  2. Wilson PW. Established risk factors and coronary artery disease (the Framingham Study). Am J Hypertens. 1994;7:7–12S
  3. Ridker PM. Evaluating novel cardiovascular risk factors (can we better predict heart attacks?). Ann Intern Med. 1999;130:933–937
  4. Melnick JL, Adam E, DeBakey ME. Possible role of cytomegalovirus in atherogenesis. JAMA. 1990;263:2204–2207
  5. Heiss G, Sharrett AR, Barnes R, et al.  Carotid atherosclerosis measured by B-mode ultrasound in populations (associations with cardiovascular risk factors in the ARIC study). Am J Epidemiol. 1991;134:250–256
  6. Sorlie PD, Nieto FJ, Adam E, et al.  A prospective study of cytomegalovirus, herpes simplex virus 1, and coronary heart disease (the atherosclerosis risk in communities (ARIC) study). Arch Intern Med. 2000;160:2027–2032
  7. Kowalski M. Helicobacter pylori (H. pylori) infection in coronary artery disease (influence of H. pylori eradication on coronary artery lumen after percutaneous transluminal coronary angioplasty: the detection of H. pylori specific DNA in human coronary atherosclerotic plaque). J Physiol Pharmacol. 2001;52(1 Suppl):3–31
  8. Kowalski M, Rees W, Konturek PC, et al.  Detection of Helicobacter pylori specific DNA in human atheromatous coronary arteries and its association to prior myocardial infarction and unstable angina. Dig Liver Dis. 2002;34:398–402
  9. Mach F, Sukhova GK, Michetti M, et al.  Influence of Helicobacter pylori infection during atherogenesis in vivo in mice. Circ Res. 2002;90:E1–4
  10. Mayr M, Kiechl S, Mendall MA, et al.  Increased risk of atherosclerosis is confined to CagA-positive Helicobacter pylori strains (prospective results from the Bruneck study). Stroke. 2003;34:610–615
  11. Chiu B. Multiple infections in carotid atherosclerotic plaques. Am Heart J. 1999;138:S534–536
  12. Morre SA, Stooker W, Lagrand WK, et al.  Microorganisms in the aetiology of atherosclerosis. J Clin Pathol. 2000;53:647–654
  13. Saikku P, Leinonen M, Mattila K, et al.  Serological evidence of an association of a novel Chlamydia, TWAR, with chronic coronary heart disease and acute myocardial infarction. Lancet. 1988;2:983–986
  14. Kuo CC, Chen HH, Wang SP, et al.  Identification of a new group of Chlamydia psittaci strains called TWAR. J Clin Microbiol. 1986;24:1034–1037
  15. Kuo CC, Jackson LA, Campbell LA, et al.  Chlamydia pneumoniae (TWAR). Clin Microbiol Rev. 1995;8:451–461
  16. Kol A, Sukhova GK, Lichtman AH, et al.  Chlamydial heat shock protein 60 localizes in human atheroma and regulates macrophage tumor necrosis factor-alpha and matrix metalloproteinase expression. Circulation. 1998;98:300–307
  17. Dowell SF, Peeling RW, Boman J, et al.  Standardizing Chlamydia pneumoniae assays (recommendations from the Centers for Disease Control and Prevention (USA) and the Laboratory Centre for Disease Control (Canada)). Clin Infect Dis. 2001;33:492–503
  18. Paltiel O, Kark JD, Leinonen M, et al.  High prevalence of antibodies to Chlamydia pneumoniae; determinants of IgG and IgA seropositivity among Jerusalem residents. Epidemiol Infect. 1995;114:465–473
  19. Mendall MA, Carrington D, Strachan D, et al.  Chlamydia pneumoniae (risk factors for seropositivity and association with coronary heart disease). J Infect. 1995;30:121–128
  20. Cook P, Honeybourne D. Chlamydia pneumoniae. J Antimicrob Chemother. 1994;34:859–873
  21. Saikku P, Leinonen M, Tenkanen L, et al.  Chronic Chlamydia pneumoniae infection as a risk factor for coronary heart disease in the Helsinki Heart Study. Ann Intern Med. 1992;116:273–278
  22. Cook PJ, Honeybourne D, Lip GY, et al.  Chlamydia pneumoniae antibody titers are significantly associated with acute stroke and transient cerebral ischemia (the West Birmingham Stroke Project). Stroke. 1998;29:404–410
  23. Sessa R, Di Pietro M, Schiavoni G, et al.  Prevalence of Chlamydia pneumoniae in peripheral blood mononuclear cells in Italian patients with acute ischaemic heart disease. Atherosclerosis. 2001;159:521–525
  24. Gaydos CA, Quinn TC, Eiden JJ. Identification of Chlamydia pneumoniae by DNA amplification of the 16S rRNA gene. J Clin Microbiol. 1992;30:796–800
  25. Danesh J, Collins R, Peto R. Chronic infections and coronary heart disease (is there a link?). Lancet. 1997;350:430–436
  26. Danesh J, Whincup P, Walker M, et al.  Chlamydia pneumoniae IgG titres and coronary heart disease (prospective study and meta-analysis). BMJ. 2000;321:208–213
  27. Danesh J, Whincup P, Lewington S, et al.  Chlamydia pneumoniae IgA titres and coronary heart disease; prospective study and meta-analysis. Eur Heart J. 2002;23:371–375
  28. Bloemenkamp DG, Mali WP, Visseren FL, et al.  Meta-analysis of sero-epidemiologic studies of the relation between Chlamydia pneumoniae and atherosclerosis (does study design influence results?). Am Heart J. 2003;145:409–417
  29. Shor A, Phillips JI, Ong G, et al.  Chlamydia pneumoniae in atheroma (consideration of criteria for causality). J Clin Pathol. 1998;51:812–817
  30. Boman J, Hammerschlag MR. Chlamydia pneumoniae and atherosclerosis (critical assessment of diagnostic methods and relevance to treatment studies). Clin Microbiol Rev. 2002;15:1–20
  31. Gaydos CA, Summersgill JT, Sahney NN, et al.  Replication of Chlamydia pneumoniae in vitro in human macrophages, endothelial cells, and aortic artery smooth muscle cells. Infect Immun. 1996;64:1614–1620
  32. Blasi F, Fagetti L, Allegra L. Chlamydia pneumoniae detection in atherosclerotic plaques in Italy. J Infect Dis. 2000;181(Suppl 3):S444–446
  33. Leowattana W, Pokum S, Mahanonda N, et al.  Rapid detection of Chlamydia pneumoniae DNA in peripheral blood mononuclear cells of coronary artery disease patients by real-time fluorescence PCR. J Med Assoc Thai. 2001;84(Suppl 3):S658–668
  34. Blasi F, Boman J, Esposito G, et al.  Chlamydia pneumoniae DNA detection in peripheral blood mononuclear cells is predictive of vascular infection. J Infect Dis. 1999;180:2074–2076
  35. Ramirez JA. Isolation of Chlamydia pneumoniae from the coronary artery of a patient with coronary atherosclerosis (the Chlamydia pneumoniae/Atherosclerosis Study Group). Ann Intern Med. 1996;125:979–982
  36. Smieja M, Mahony J, Petrich A, et al.  Association of circulating Chlamydia pneumoniae DNA with cardiovascular disease (a systematic review). BMC Infect Dis. 2002;2:21
  37. Bartels C, Maass M, Bein G, et al.  Association of serology with the endovascular presence of Chlamydia pneumoniae and cytomegalovirus in coronary artery and vein graft disease. Circulation. 2000;101:137–141
  38. Berger M, Schroder B, Daeschlein G, et al.  Chlamydia pneumoniae DNA in non-coronary atherosclerotic plaques and circulating leukocytes. J Lab Clin Med. 2000;136:194–200
  39. Laitinen K, Laurila A, Pyhala L, et al.  Chlamydia pneumoniae infection induces inflammatory changes in the aortas of rabbits. Infect Immun. 1997;65:4832–4835
  40. Muhlestein JB, Anderson JL, Hammond EH, et al.  Infection with Chlamydia pneumoniae accelerates the development of atherosclerosis and treatment with azithromycin prevents it in a rabbit model. Circulation. 1998;97:633–636
  41. Laurila A, Bloigu A, Nayha S, et al.  Chronic Chlamydia pneumoniae infection is associated with a serum lipid profile known to be a risk factor for atherosclerosis. Arterioscler Thromb Vasc Biol. 1997;17:2910–2913
  42. Leinonen M, Saikku P. Interaction of Chlamydia pneumoniae infection with other risk factors of atherosclerosis. Am Heart J. 1999;138:S504–506
  43. Libby P, Sukhova G, Lee RT, et al.  Cytokines regulate vascular functions related to stability of the atherosclerotic plaque. J Cardiovasc Pharmacol. 1995;25(Suppl 2):S9–12
  44. Molestina RE, Miller RD, Lentsch AB, et al.  Requirement for NF-kappaB in transcriptional activation of monocyte chemotactic protein 1 by Chlamydia pneumoniae in human endothelial cells. Infect Immun. 2000;68:4282–4288
  45. Dechend R, Maass M, Gieffers J, et al.  Chlamydia pneumoniae infection of vascular smooth muscle and endothelial cells activates NF-kappaB and induces tissue factor and PAI-1 expression (a potential link to accelerated arteriosclerosis). Circulation. 1999;100:1369–1373
  46. Airenne S, Surcel HM, Tuukkanen J, et al.  Chlamydia pneumoniae inhibits apoptosis in human epithelial and monocyte cell lines. Scand J Immunol. 2002;55:390–398
  47. Carratelli CR, Rizzo A, Catania MR, et al.  Chlamydia pneumoniae infections prevent the programmed cell death on THP-1 cell line. FEMS Microbiol Lett. 2002;215:69–74
  48. Toss H, Gnarpe J, Gnarpe H, et al.  Increased fibrinogen levels are associated with persistent Chlamydia pneumoniae infection in unstable coronary artery disease. Eur Heart J. 1998;19:570–577
  49. Fryer RH, Schwobe EP, Woods ML, et al.  Chlamydia species infect human vascular endothelial cells and induce procoagulant activity. J Investig Med. 1997;45:168–174
  50. Gieffers J, Solbach W, Maass M. In vitro susceptibility and eradication of Chlamydia pneumoniae cardiovascular strains from coronary artery endothelium and smooth muscle cells. Cardiovasc Drugs Ther. 2001;15:259–262
  51. Melissano G, Blasi F, Esposito G, et al.  Chlamydia pneumoniae eradication from carotid plaques (results of an open, randomised treatment study). Eur J Vasc Endovasc Surg. 1999;18:355–359
  52. Anderson JL, Muhlestein JB, Carlquist J, et al.  Randomized secondary prevention trial of azithromycin in patients with coronary artery disease and serological evidence for Chlamydia pneumoniae infection. The Azithromycin in Coronary Artery Disease (Elimination of Myocardial Infection with Chlamydia (ACADEMIC) study). Circulation. 1999;99:1540–1547
  53. Gupta S. Chlamydia pneumoniae, monocyte activation, and azithromycin in coronary heart disease. Am Heart J. 1999;138:S539–541
  54. Hansen S, Als-Nielsen B, Damgaard M, et al.  Intervention with clarithromycin in patients with stable coronary heart disease (the CLARICOR Trial Design). Heart Drug. 2001;1:14–19
  55. Jackson LA. Description and status of the azithromycin and coronary events study (ACES). J Infect Dis. 2000;181(3 Suppl):S579–581
  56. Gupta S, Leatham EW, Carrington D, et al.  Elevated Chlamydia pneumoniae antibodies, cardiovascular events, and azithromycin in male survivors of myocardial infarction. Circulation. 1997;96:404–407
  57. Clinical trials 2002. WIZARD: Weekly Intervention with Zithromax for Atherosclerosis and its Related Disorders. Available at: http://wwww.cardiosource.com. Accessed December 10, 2003
  58. Larsen MM, Moern B, Fuller A, et al. Chlamydia pneumoniae and cardiovascular disease. Med J Austr 2002;177:558–62
  59. Gurfinkel E, Bozovich G, Beck E, et al.  Treatment with the antibiotic roxithromycin in patients with acute non-Q-wave coronary syndromes (the final report of the ROXIS Study). Eur Heart J. 1999;20:121–127
  60. Leowattana W, Bhuripanyo K, Singhaviranon L, et al.  Roxithromycin in prevention of acute coronary syndrome associated with Chlamydia pneumoniae infection (a randomized placebo controlled trial). J Med Assoc Thai. 2001;84(3 Suppl):S669–675
  61. Stone AF, Mendall MA, Kaski JC, et al.  Effect of treatment for Chlamydia pneumoniae and Helicobacter pylori on markers of inflammation and cardiac events in patients with acute coronary syndromes (South Thames Trial of Antibiotics in Myocardial Infarction and Unstable Angina (STAMINA)). Circulation. 2002;106:1219–1223
  62. Sinisalo J, Mattila K, Valtonen V, et al.  Effect of 3 months of antimicrobial treatment with clarithromycin in acute non-Q-wave coronary syndrome. Circulation. 2002;105:1555–1560
  63. Cercek B, Shah PK, Noc M, et al.  Effect of short-term treatment with azithromycin on recurrent ischaemic events in patients with acute coronary syndrome in the Azithromycin in Acute Coronary Syndrome (AZACS) trial (a randomised controlled trial). Lancet. 2003;361:809–813
  64. Zahn R, Schneider S, Frilling B, et al.  Antibiotic therapy after acute myocardial infarction (a prospective randomized study). Circulation. 2003;107:1253–1259
  65. Cannon CP, McCabe CH, Belder R, et al.  Design of the Pravastatin or Atorvastatin Evaluation and Infection Therapy (PROVE IT)-TIMI 22 trial. Am J Cardiol. 2002;89:860–861
  66. Neumann F, Kastrati A, Miethke T, et al.  Treatment of Chlamydia pneumoniae infection with roxithromycin and effect on neointima proliferation after coronary stent placement (ISAR-3) (a randomised, double-blind, placebo-controlled trial). Lancet. 2001;357:2085–2089
  67. Gurfinkel E, Bozovich G, Daroca A, et al.  Randomised trial of roxithromycin in non-Q-wave coronary syndromes (ROXIS Pilot Study. ROXIS Study Group). Lancet. 1997;350:404–407

PII: S0002-8703(03)00652-5

doi: 10.1016/j.ahj.2003.09.011

American Heart Journal
Volume 147, Issue 2 , Pages 202-209 , February 2004

Article Tools

* Image Usage & Resolution